# Comparison of eptinezumab 300 mg with 100 mg for the treatment of migraine: a meta-analysis of randomized controlled studies

## TL;DR

This study compares two doses of eptinezumab for migraine treatment and finds that the higher dose may be more effective.

## Contribution

A meta-analysis comparing 300 mg and 100 mg eptinezumab for migraine efficacy and safety.

## Key findings

- Eptinezumab 300 mg showed improved 75% responder rates compared to 100 mg.
- No significant differences were found in monthly migraine days or adverse events between the two doses.

## Abstract

The efficacy and safety of eptinezumab 300 mg versus 100 mg for migraine remains debatable. We conduct this meta-analysis to compare eptinezumab 300 mg with 100 mg on the treatment of migraine.

We have searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through April 2021 for randomized controlled trials (RCTs) assessing the effect of eptinezumab 300 mg versus 100 mg on treatment efficacy and safety in migraine patients. This meta-analysis was performed using the random-effect model.

Four RCTs were included in the meta-analysis. Overall, compared with eptinezumab 100 mg in migraine patients, eptinezumab 300 mg was associated with substantially improved 75% responder rate (OR=1.34; 95% CI=1.06 to 1.69; P=0.01), but demonstrated similar monthly migraine days (MD=-0.09; 95% CI=-0.20 to 0.01; P=0.08), 100% responder rate (OR=1.38; 95% CI=0.94 to 2.02; P=0.10), 50% responder rate (OR=1.20; 95% CI=0.97 to 1.48; P=0.10), migraine 1 day after dosing (OR=0.92; 95% CI=0.72 to 1.18; P=0.52), adverse events (OR=1.13; 95% CI=0.77 to 1.65; P=0.53), nasopharyngitis (OR=1.26; 95% CI=0.74 to 2.14; P=0.40), upper respiratory tract infection (OR=1.25; 95% CI=0.83 to 1.88; P=0.29), sinusitis (OR=1.78; 95% CI=0.95 to 3.33; P=0.07) or nausea (OR=1.26; 95% CI=0.68 to 2.32; P=0.46).

Eptinezumab 300 mg may have better efficacy for migraine patients than eptinezumab 100 mg.